Get the Stockscreener App
228.35
0.37%
-0.84
After Hours:
228.35
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $228.35, with a volume of 837.61K.
It is down -0.37% in the last 24 hours and up +2.33% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
See More
Previous Close:
$229.19
Open:
$225.91
24h Volume:
837.61K
Relative Volume:
0.58
Market Cap:
$32.94B
Revenue:
$5.54B
Net Income/Loss:
$1.52B
P/E Ratio:
22.01
EPS:
10.3734
Net Cash Flow:
$1.74B
1W Performance:
-4.98%
1M Performance:
+2.33%
6M Performance:
-11.85%
1Y Performance:
-16.60%
1-Day Range:
$225.12
$228.49
1-Week Range:
$225.12
$242.40
52-Week Range:
$180.26
$284.87
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
228.35 | 32.95B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
366.70 | 132.30B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
184.74 | 51.11B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
70.50 | 35.25B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
36.59 | 28.58B | 29.14B | 1.07B | 1.05B | 1.1956 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | JP Morgan | Overweight |
| Dec-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-18-25 | Initiated | Citigroup | Buy |
| Sep-02-25 | Upgrade | CLSA | Hold → Outperform |
| Jul-15-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-19-25 | Initiated | Morgan Stanley | Overweight |
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
ResMed Inc. stock gains on FY2026 growth and buyback launch - AD HOC NEWS
ResMed Inc Reports August 2026 CHESS Depositary Interests and Securities Update - Kalkine Media
Paralel Advisors LLC Purchases Shares of 10,293 ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Shares Acquired by Giverny Capital Inc. - MarketBeat
Why Is ResMed (ASX:RMD) Sustaining Home-Care Demand? - Kalkine Media
ResMed Director Peter Farrell Sells 970 Shares Under Rule 10b5-1 Plan - Kalkine
ResMed Inc. stock holds above support as fiscal 2026 growth and cautious 2027 outlook shape sentimen - AD HOC NEWS
ResMed Director Peter Farrell Executes Sale of 970 Shares via 10b5-1 Trading Plan - Kalkine Media
ResMed chairman emeritus Peter Farrell sells $227,688 in stock By Investing.com - Investing.com South Africa
ResMed (NYSE:RMD) Director Peter Farrell Sells 970 Shares - MarketBeat
ResMed (RMD) director sells shares under trading plan - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc.RMD - PR Newswire
Nykredit A S Acquires New Position in ResMed Inc. $RMD - MarketBeat
ResMed (NYSE:RMD): A Quality Dividend Play Built on Sustainable Payouts - ChartMill
Jupiter Topco LLC Takes Position in ResMed Inc. $RMD - MarketBeat
Director at ResMed (NYSE: RMD) plans new 970-share stock sale - Stock Titan
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 9,064 Shares of ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Shares Sold by Van ECK Associates Corp - MarketBeat
ResMed (RMD) Announces $450 Million Accelerated Share Repurchase Agreement - GuruFocus
ResMed Enters $450 Million Accelerated Share Repurchase Agreement With Citibank; Shares Fall 3% - Moomoo
Is ResMed Inc (RMD) a Bargain After 3.6% Drop? GF Value Says Und - GuruFocus
ResMed Launches $450 Million Accelerated Share Buyback With Citibank - marketscreener.com
ResMed Inc. stock falls Tuesday, underperforms market - MarketWatch
ResMed (NYSE: RMD) plans to use MatrixCare sale cash for fast-track buyback - Stock Titan
Resmed Inc Stock (RMD) Moved Down by 3.25% on Sep 1: Facts Behind the Movement - TradingKey
Frazier Healthcare completes acquisition of MatrixCare from ResMed By Investing.com - Investing.com South Africa
MatrixCare software serves more than 15,000 providers. Frazier completes the acquisition. - Stock Titan
Quantitative Investment Management LLC Invests $2.21 Million in ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Stock Position Raised by Railway Pension Investments Ltd - MarketBeat
Public Employees Retirement System of Ohio Takes $9.75 Million Position in ResMed Inc. $RMD - MarketBeat
ResMed Inc. (NYSE:RMD) Given Average Rating of "Hold" by Brokerages - MarketBeat
ResMed Unlocks A Bigger Sleep-Health Ecosystem With OURA And Noctrix! - Smartkarma
Frazier Management, L.L.C. completed the acquisition of MatrixCare, Inc. from ResMed Inc.. - marketscreener.com
KeyBanc raises ResMed stock price target on FY27 outlook confidence - Investing.com
Rakuten Investment Management Inc. Takes Position in ResMed Inc. $RMD - MarketBeat
ResMed Inc. (RMD) Stock Analysis: Navigating Growth with 8.6% Revenue Surge and Promising 2.15% Upside - DirectorsTalk Interviews
KeyBanc Maintains ResMed(RMD.US) With Buy Rating, Raises Target Price to $267 - Moomoo
Manulife buys $14.4M ResMed stake as revenue climbs 8.6% - Dealroom
GTS Securities LLC Has $2.05 Million Holdings in ResMed Inc. $RMD - MarketBeat
United Capital Financial Advisors LLC Purchases New Holdings in ResMed Inc. $RMD - MarketBeat
Freestone Grove Partners LP Invests $1.52 Million in ResMed Inc. $RMD - MarketBeat
The Manufacturers Life Insurance Company Makes New Investment in ResMed Inc. $RMD - MarketBeat
Corient Private Wealth LP Purchases Shares of 85,266 ResMed Inc. $RMD - MarketBeat
Empowered Funds LLC Buys New Shares in ResMed Inc. $RMD - MarketBeat
ResMed Inc. stock rises Friday, outperforms market - MarketWatch
MASTERINVEST Kapitalanlage GmbH Takes $3.77 Million Position in ResMed Inc. $RMD - MarketBeat
Hsbc Holdings PLC Buys Shares of 355,518 ResMed Inc. $RMD - MarketBeat
Man Group plc Makes New Investment in ResMed Inc. $RMD - MarketBeat
Ieq Capital LLC Acquires New Position in ResMed Inc. $RMD - MarketBeat
Northwestern Mutual Wealth Management Co. Invests $946,000 in ResMed Inc. $RMD - MarketBeat
Korea Investment CORP Invests $9.85 Million in ResMed Inc. $RMD - MarketBeat
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
2.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):